BackKaryopharm Therapeutics Overview

Karyopharm Therapeutics Cost of Revenue

Cost of Revenue analysis for KPTI.

Quarterly Cost of Revenue

$1.36M
↑ 4.3% YoY

As of Mar 31, 2026

Annual Cost of Revenue (TTM)

$6.00M
↑ 9.42% YoY

Trailing 12 months ending Mar 31, 2026

Average Cost of Revenue (Comparison Companies)

Cost of Revenue History

Cost of Revenue Comparison

Annual Cost of Revenue Growth Rate (%)

Annual Cost of Revenue Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin